secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001516551-24-000093
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience appoints Paul Grayson as Chairman; CEO Dhillon gets salary hike and stock options
--------------------------------------------------------------------------------

- Paul Grayson appointed Chairman effective Oct 25, 2024; CEO Punit Dhillon resigns as Chairman, remains on Board.
- CEO Dhillon's base salary increased to $610,000; CFO Arsenault's to $450,000, effective Jan 1, 2025.
- Stock options granted: Dhillon 650,000 shares, Arsenault 125,000 shares; 10-year term, 48-month vesting.
- Grayson is independent director; currently CEO of Radionetics Oncology, former CEO of Tentarix and founder at Fate Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000093/0001516551-24-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000093/skye-20241028.htm
  HTML page:      https://secwatch.observer/filing/0001516551-24-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer